How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example

Blood Pressure
Julie BulseiDENERHTN Study Group

Abstract

Whilst much uncertainty exists as to the efficacy of renal denervation (RDN), the positive results of the DENERHTN study in France confirmed the interest of an economic evaluation in order to assess efficiency of RDN and inform local decision makers about the costs and benefits of this intervention. The uncertainty surrounding both the outcomes and the costs can be described using health economic methods such as the non-parametric bootstrap. Internationally, numerous health economic studies using a cost-effectiveness model to assess the impact of RDN in terms of cost and effectiveness compared to antihypertensive medical treatment have been conducted. The DENERHTN cost-effectiveness study was the first health economic evaluation specifically designed to assess the cost-effectiveness of RDN using individual data. Using the DENERHTN results as an example, we provide here a summary of the principle methods used to perform a cost-effectiveness analysis.

References

May 1, 1997·Health Economics·M J BuxtonM Vray
Jun 6, 2003·European Heart Journal·R M ConroyUNKNOWN SCORE project group
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Elisabeth Fenwick, Sarah Byford
Jan 24, 2008·Circulation·Ralph B D'AgostinoWilliam B Kannel
May 6, 2011·Diabetes Care·Ehud Grossman
Apr 4, 2012·Journal of Hypertension·Roland E SchmiederCostas Tsioufis
Sep 18, 2012·Journal of the American College of Cardiology·Benjamin P GeislerJan B Pietzsch
Mar 30, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Don HusereauUNKNOWN ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force
Apr 27, 2013·European Heart Journal·Felix MahfoudUNKNOWN European Society of Cardiology
Apr 1, 2014·The New England Journal of Medicine·Deepak L BhattUNKNOWN SYMPLICITY HTN-3 Investigators
Aug 5, 2014·Applied Health Economics and Health Policy·Daniel GladwellRon Akehurst
Apr 29, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Kazuomi KarioUNKNOWN SYMPLICITY HTN-Japan Investigators
Nov 1, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·D TildenJ Gillespie
Mar 8, 2017·Hypertension·Rosa L de JagerUNKNOWN SYMPATHY Investigators
Apr 27, 2017·Blood Pressure·Fadl Elmula M Fadl ElmulaUNKNOWN European Network COordinating research on Renal Denervation (ENCOReD)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Thea HenryH Koffijberg
Medicina clínica
Enrique GalveGrupo de consenso español sobre denervación renal
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
H Y KangH Lee
© 2022 Meta ULC. All rights reserved